BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Study phase III, randomized, double-dummy, placebo controlled, single-center, of regarding the non-inferiority of the medication BL3000, when compared to Pantogar® treatment of telogen effluvium in women. Research product: BL3000. Reference product: Pantogar® List of Study Center: MAIN INVESTIGATOR STUDY CENTER FONE Medcin Skin Institute Sérgio Schalka 11 36835357
Epistemonikos ID: f601663aa2ba85a9401d65086a2e3ba9243e53e5
First added on: May 08, 2024